286 related articles for article (PubMed ID: 32524284)
1. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.
Weykamp F; Seidensaal K; Rieken S; Green K; Mende S; Zaoui K; Freier K; Adeberg S; Debus J; Welte SE
Strahlenther Onkol; 2020 Jun; 196(6):515-521. PubMed ID: 31784802
[TBL] [Abstract][Full Text] [Related]
5. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
6. Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer.
Trevisani F; Di Marco F; Quattrini G; Lepori N; Floris M; Valsecchi D; Giordano L; Dell'Oca I; Cardellini S; Cinque A; Mirabile A
Front Oncol; 2023; 13():1173578. PubMed ID: 37361572
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
[TBL] [Abstract][Full Text] [Related]
8. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
9. Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study.
Ohkoshi A; Ishii R; Wakamori S; Nakayama Y; Yoshida T; Higashi K; Nakanome A; Ogawa T; Katori Y
Oral Oncol; 2021 Oct; 121():105475. PubMed ID: 34364132
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma.
Powell SF; Mazurczak M; Dib EG; Bleeker JS; Geeraerts LH; Tinguely M; Lohr MM; McGraw SC; Jensen AW; Ellison CA; Black LJ; Puumala SE; Reed VJ; Miskimins WK; Lee JH; Spanos WC
Invest New Drugs; 2022 Jun; 40(3):622-633. PubMed ID: 35312941
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
12. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract][Full Text] [Related]
14. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer.
Driessen CM; Uijen MJ; van der Graaf WT; van Opstal CC; Kaanders JH; Nijenhuis T; van Herpen CM
Head Neck; 2016 Apr; 38 Suppl 1():E1575-81. PubMed ID: 26614010
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
17. Effect of mannitol-based reduced-volume hydration on kidney function in concomitant cisplatin-based chemoradiation for head-and-neck squamous cell carcinoma.
Paschen C; Moll M; Altorjai G; Hecking M; Fuereder T; Widder J; Herrmann H
Head Neck; 2023 Aug; 45(8):2087-2097. PubMed ID: 37345576
[TBL] [Abstract][Full Text] [Related]
18. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
20. Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients.
Mapuskar KA; Vasquez Martinez G; Pulliam CF; Petronek MS; Steinbach EJ; Monga V; Furqan M; Jetton JG; Saunders DP; Pearce A; Davidson S; Pitre L; Dunlap NE; Fairbanks R; Lee CM; Mott SL; Bodeker KL; Cl H; Buatti JM; Anderson CM; Beardsley RA; Holmlund JT; Zepeda-Orozco D; Spitz DR; Allen BG
Redox Biol; 2023 Apr; 60():102599. PubMed ID: 36640725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
